首页 > 最新文献
paperpass

Oncoimmunology最新文献

英文 中文
Store-operated calcium signaling modulators improve a dendritic cell-based vaccine against melanoma. 储存操作的钙信号调节剂改善了基于树突状细胞的黑色素瘤疫苗。
IF 6.2 2区 医学 Q1 IMMUNOLOGY Pub Date : 2026-12-31 Epub Date: 2026-08-28 DOI: 10.1080/2162402X.2026.2723541
María Cruz Cobo, Laure Garnier, Marion Mandavit, Maral Azam, Isabelle Dentand Quadri, Julien Angelillo, Dale Brighouse, Mathilde Bausart, Valérie Dutoit, Achille Schild, Valeria M Oliva, Martin Lochner, Bénédicte Manoury, Stéphanie Hugues, Paula Nunes-Hasler

Summary: Cruz Cobo et al. identify small molecules that reprogram dendritic cells toward an immuno-stimulating secretory phenotype, revealing endoplasmic reticulum calcium signaling as a druggable axis to boost vaccine-based and T cell-mediated cancer immunotherapies. The study links broad changes in calcium-induced secretion to improved immune activation and therapeutic potency.

{"title":"Store-operated calcium signaling modulators improve a dendritic cell-based vaccine against melanoma.","authors":"María Cruz Cobo, Laure Garnier, Marion Mandavit, Maral Azam, Isabelle Dentand Quadri, Julien Angelillo, Dale Brighouse, Mathilde Bausart, Valérie Dutoit, Achille Schild, Valeria M Oliva, Martin Lochner, Bénédicte Manoury, Stéphanie Hugues, Paula Nunes-Hasler","doi":"10.1080/2162402X.2026.2723541","DOIUrl":"10.1080/2162402X.2026.2723541","url":null,"abstract":"<p><strong>Summary: </strong>Cruz Cobo et al. identify small molecules that reprogram dendritic cells toward an immuno-stimulating secretory phenotype, revealing endoplasmic reticulum calcium signaling as a druggable axis to boost vaccine-based and T cell-mediated cancer immunotherapies. The study links broad changes in calcium-induced secretion to improved immune activation and therapeutic potency.</p>","PeriodicalId":48714,"journal":{"name":"Oncoimmunology","volume":"15 1","pages":"2723541"},"PeriodicalIF":6.2,"publicationDate":"2026-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13531994/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148851662","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A novel oncolytic peptide synergizing with immunotherapy. 与免疫疗法协同作用的新型溶瘤肽。
IF 6.2 2区 医学 Q1 IMMUNOLOGY Pub Date : 2026-12-31 Epub Date: 2026-10-01 DOI: 10.1080/2162402X.2026.2740845
Guido Kroemer, Xiaolian Deng, Baldur Sveinbjørnsson, Oliver Kepp

In a recent paper published in Nature, Yuan et al. described an acid-responsive membranolytic peptide that temporally separates lysosomes from later plasma membrane rupture, thereby converting oncolysis into immunogenic cell death. This elegant design permits systemic administration, elicits antigen-specific immunity, and sensitizes tumors to programmed death ligand 1 blockade with remarkably limited toxicity.

在最近发表在《自然》杂志上的一篇论文中,Yuan等人描述了一种酸反应性膜分解肽,它可以暂时地将溶酶体与随后的质膜破裂分离,从而将肿瘤溶解转化为免疫原性细胞死亡。这种优雅的设计允许全身给药,引发抗原特异性免疫,并使肿瘤对程序死亡配体1阻断敏感,毒性非常有限。
{"title":"A novel oncolytic peptide synergizing with immunotherapy.","authors":"Guido Kroemer, Xiaolian Deng, Baldur Sveinbjørnsson, Oliver Kepp","doi":"10.1080/2162402X.2026.2740845","DOIUrl":"10.1080/2162402X.2026.2740845","url":null,"abstract":"<p><p>In a recent paper published in Nature, Yuan et al. described an acid-responsive membranolytic peptide that temporally separates lysosomes from later plasma membrane rupture, thereby converting oncolysis into immunogenic cell death. This elegant design permits systemic administration, elicits antigen-specific immunity, and sensitizes tumors to programmed death ligand 1 blockade with remarkably limited toxicity.</p>","PeriodicalId":48714,"journal":{"name":"Oncoimmunology","volume":"15 1","pages":"2740845"},"PeriodicalIF":6.2,"publicationDate":"2026-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13641581/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149116728","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Irradiated dendritic cell subsets retain key immune capabilities and anti-tumor immunity is not strictly dependent on cDC1. 辐照的树突状细胞亚群保留了关键的免疫能力,抗肿瘤免疫并不严格依赖于cDC1。
IF 6.2 2区 医学 Q1 IMMUNOLOGY Pub Date : 2026-12-31 Epub Date: 2026-10-29 DOI: 10.1080/2162402X.2026.2743436
Teresa Irianto, Ann-Sophie Flohr, Clara Reichardt, Ateeqa Ghuias, Lisa Weissmann, Detlef Freitag, Lukas Amon, Christian H K Lehmann, Diana Dudziak, Kai Hildner, Stefanie Corradini, Benjamin Frey, Udo S Gaipl, Michael Rückert

Radiotherapy can enhance anti-tumor immunity by modulating the tumor microenvironment. However, its direct effects on dendritic cells (DCs) as key antigen-presenting cells remain poorly studied. Although DCs are considered relatively radioresistant, their functional capacity following irradiation is controversial and likely subset-dependent. In this study, we systematically analyzed the radiosensitivity and post-irradiation functional capacity of murine bone marrow-derived conventional type 1 DCs (cDC1s), which play a pivotal role in initiating CD8+ T cell-mediated anti-tumor immunity, conventional type 2 DCs (cDC2s), and monocyte-derived DCs (MoDCs) in vitro. After irradiation, DC viability and surface marker expression were assessed. To evaluate functional competence, DCs were stimulated with high hydrostatic pressure-inactivated tumor cells in combination with the adjuvants poly I:C and α-CD40 as a model system for therapeutic tumor vaccination, and the phagocytic activity, activation, and cytokine/chemokine secretion of the DCs were analyzed. DC radiosensitivity depended strongly on both the subset and maturation state, with mature DCs showing higher radioresistance than their immature counterparts, and with immature cDC1s being particularly more susceptible. Nevertheless, surviving DCs retained their ability to phagocytose tumor cells and, upon stimulation, upregulate activation- and migration-associated markers and secrete cytokines and chemokines. In vivo, radio-immunotherapy promoted DC migration to the tumor-draining lymph node and induced DC activation, as indicated by elevated concentrations of DC-related cytokines in the peripheral blood. Within a fixed radiotherapy plus checkpoint inhibition regimen, tumor growth delay was largely preserved in Batf3-/- mice, lacking the cDC1 subset. Collectively, irradiation does not abrogate DC function, and anti-tumor immunity in radio-immunotherapy does not strictly require cDC1s.

放疗可通过调节肿瘤微环境增强抗肿瘤免疫。然而,其对作为关键抗原呈递细胞的树突状细胞(dc)的直接影响尚不清楚。虽然dc被认为是相对耐辐射的,但它们在辐照后的功能能力是有争议的,可能与亚群有关。在这项研究中,我们系统地分析了小鼠骨髓来源的常规1型dc (cDC1s)的放射敏感性和辐照后功能能力,cDC1s在启动CD8+ T细胞介导的抗肿瘤免疫中起关键作用,常规2型dc (cDC2s)和单核细胞来源dc (MoDCs)在体外。照射后,评估DC活力和表面标志物表达。为了评估功能能力,我们将高静水压力灭活的肿瘤细胞与佐剂poly I:C和α-CD40联合刺激dc作为治疗性肿瘤疫苗接种的模型系统,并分析dc的吞噬活性、活化和细胞因子/趋化因子分泌。DC放射敏感性强烈依赖于亚群和成熟状态,成熟DC比未成熟DC表现出更高的放射抗性,未成熟cDC1s尤其易受影响。然而,存活的树突状细胞保留了吞噬肿瘤细胞的能力,并在刺激下上调激活和迁移相关标记,分泌细胞因子和趋化因子。在体内,放射免疫治疗促进DC向肿瘤引流淋巴结迁移,并诱导DC活化,外周血中DC相关细胞因子浓度升高。在固定放疗加检查点抑制方案中,在缺乏cDC1亚群的Batf3-/-小鼠中,肿瘤生长延迟在很大程度上得以保留。综上所述,辐照并没有剥夺DC的功能,放射免疫治疗中的抗肿瘤免疫并不严格要求cDC1s。
{"title":"Irradiated dendritic cell subsets retain key immune capabilities and anti-tumor immunity is not strictly dependent on cDC1.","authors":"Teresa Irianto, Ann-Sophie Flohr, Clara Reichardt, Ateeqa Ghuias, Lisa Weissmann, Detlef Freitag, Lukas Amon, Christian H K Lehmann, Diana Dudziak, Kai Hildner, Stefanie Corradini, Benjamin Frey, Udo S Gaipl, Michael Rückert","doi":"10.1080/2162402X.2026.2743436","DOIUrl":"10.1080/2162402X.2026.2743436","url":null,"abstract":"<p><p>Radiotherapy can enhance anti-tumor immunity by modulating the tumor microenvironment. However, its direct effects on dendritic cells (DCs) as key antigen-presenting cells remain poorly studied. Although DCs are considered relatively radioresistant, their functional capacity following irradiation is controversial and likely subset-dependent. In this study, we systematically analyzed the radiosensitivity and post-irradiation functional capacity of murine bone marrow-derived conventional type 1 DCs (cDC1s), which play a pivotal role in initiating CD8<sup>+</sup> T cell-mediated anti-tumor immunity, conventional type 2 DCs (cDC2s), and monocyte-derived DCs (MoDCs) <i>in vitro</i>. After irradiation, DC viability and surface marker expression were assessed. To evaluate functional competence, DCs were stimulated with high hydrostatic pressure-inactivated tumor cells in combination with the adjuvants poly I:C and α-CD40 as a model system for therapeutic tumor vaccination, and the phagocytic activity, activation, and cytokine/chemokine secretion of the DCs were analyzed. DC radiosensitivity depended strongly on both the subset and maturation state, with mature DCs showing higher radioresistance than their immature counterparts, and with immature cDC1s being particularly more susceptible. Nevertheless, surviving DCs retained their ability to phagocytose tumor cells and, upon stimulation, upregulate activation- and migration-associated markers and secrete cytokines and chemokines. <i>In vivo</i>, radio-immunotherapy promoted DC migration to the tumor-draining lymph node and induced DC activation, as indicated by elevated concentrations of DC-related cytokines in the peripheral blood. Within a fixed radiotherapy plus checkpoint inhibition regimen, tumor growth delay was largely preserved in Batf3<sup>-/-</sup> mice, lacking the cDC1 subset. Collectively, irradiation does not abrogate DC function, and anti-tumor immunity in radio-immunotherapy does not strictly require cDC1s.</p>","PeriodicalId":48714,"journal":{"name":"Oncoimmunology","volume":"15 1","pages":"2743436"},"PeriodicalIF":6.2,"publicationDate":"2026-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13733152/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149301484","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cancer patient outcomes correlate with activating-KIR/ligand repertoires associated with distinct NK cell transcriptomic profiles. 癌症患者的预后与与不同NK细胞转录组谱相关的激活kir /配体谱相关。
IF 6.2 2区 医学 Q1 IMMUNOLOGY Pub Date : 2026-12-31 Epub Date: 2026-11-04 DOI: 10.1080/2162402X.2026.2756722
Inmaculada Ruiz-Lorente, Andrés Vallejo-Pulido, Alicia López-Abad, Pedro López Cubillana, Víctor Barozi, Salim I Khakoo, Alfredo Minguela, Lourdes Gimeno

Background: Rates of cancer cure increase; however, recurrence and refractoriness remain clinical challenges that require alternative therapeutic strategies. Natural killer (NK) cells could play a decisive role if their antitumor reactivity can be enhanced. The interaction between killer-cell immunoglobulin-like receptors (KIRs) and their human leukocyte antigen class-I (HLA-I) ligands significantly influences NK-cell education and may impact clinical outcomes in cancer patients. In this study, we evaluated the impact of KIR/HLA-I interactions on the transcriptomic profile of circulating NK-cells and their association with patient outcome.

Methods: KIR and HLA-I genotyping, together with KIR expression analysis in circulating NK cells, were performed in patients with solid and hematologic malignancies (n = 1,153). In addition, single-cell transcriptomic analyses (scRNA-seq) of circulating NK and T lymphocytes were carried out in selected donors with KIR/HLA-I genotypes associated with short and long survival.

Results: Activating KIRs (aKIRs), more than inhibitory KIRs, were associated with cancer patient outcomes. The accumulation of aKIR-HLA interactions was related to shorter overall survival, whereas KIR2DS1/C2 interaction, in the absence of other aKIR interactions, was associated with longer survival. Three major NK-cell transcriptional profiles were identified: mature cytotoxic, immature/regulatory, and adaptive cytotoxic. The adaptive-like transcriptional profile was associated with longer survival.

Conclusions: In conclusion, aKIR/HLA-I interactions were associated with cancer patient outcomes. In particular, KIR2DS1/C2 interaction in the absence of other activating signals was associated with adaptive NK-cell transcriptomic profiles and improved survival. Understanding the mechanisms underlying effective NK-cell-mediated tumor immunity may provide new opportunities for patients with refractory tumors.

背景:癌症治愈率上升;然而,复发和难治性仍然是临床挑战,需要其他治疗策略。自然杀伤细胞(NK)若能增强其抗肿瘤活性,将在肿瘤治疗中发挥决定性作用。杀伤细胞免疫球蛋白样受体(KIRs)与其人类白细胞抗原i类(HLA-I)配体之间的相互作用显著影响nk细胞教育,并可能影响癌症患者的临床结果。在这项研究中,我们评估了KIR/ hla - 1相互作用对循环nk细胞转录组谱的影响及其与患者预后的关系。方法:对1153例实体和血液学恶性肿瘤患者进行KIR和hla - 1基因分型,并分析循环NK细胞中KIR的表达。此外,对与短期和长期生存相关的KIR/ hla - 1基因型供者进行循环NK和T淋巴细胞的单细胞转录组分析(scRNA-seq)。结果:与抑制KIRs相比,激活KIRs (aKIRs)与癌症患者的预后相关。aKIR- hla相互作用的积累与较短的总生存期有关,而KIR2DS1/C2相互作用在没有其他aKIR相互作用的情况下与较长的生存期有关。确定了三种主要的nk细胞转录谱:成熟细胞毒性,未成熟/调节性和适应性细胞毒性。适应性转录谱与更长的生存期相关。结论:总之,aKIR/ hla - 1相互作用与癌症患者的预后相关。特别是,在缺乏其他激活信号的情况下,KIR2DS1/C2相互作用与适应性nk细胞转录组谱和生存率的提高有关。了解nk细胞介导的有效肿瘤免疫机制可能为难治性肿瘤患者提供新的机会。
{"title":"Cancer patient outcomes correlate with activating-KIR/ligand repertoires associated with distinct NK cell transcriptomic profiles.","authors":"Inmaculada Ruiz-Lorente, Andrés Vallejo-Pulido, Alicia López-Abad, Pedro López Cubillana, Víctor Barozi, Salim I Khakoo, Alfredo Minguela, Lourdes Gimeno","doi":"10.1080/2162402X.2026.2756722","DOIUrl":"https://doi.org/10.1080/2162402X.2026.2756722","url":null,"abstract":"<p><strong>Background: </strong>Rates of cancer cure increase; however, recurrence and refractoriness remain clinical challenges that require alternative therapeutic strategies. Natural killer (NK) cells could play a decisive role if their antitumor reactivity can be enhanced. The interaction between killer-cell immunoglobulin-like receptors (KIRs) and their human leukocyte antigen class-I (HLA-I) ligands significantly influences NK-cell education and may impact clinical outcomes in cancer patients. In this study, we evaluated the impact of KIR/HLA-I interactions on the transcriptomic profile of circulating NK-cells and their association with patient outcome.</p><p><strong>Methods: </strong>KIR and HLA-I genotyping, together with KIR expression analysis in circulating NK cells, were performed in patients with solid and hematologic malignancies (<i>n</i> = 1,153). In addition, single-cell transcriptomic analyses (scRNA-seq) of circulating NK and T lymphocytes were carried out in selected donors with KIR/HLA-I genotypes associated with short and long survival.</p><p><strong>Results: </strong>Activating KIRs (aKIRs), more than inhibitory KIRs, were associated with cancer patient outcomes. The accumulation of aKIR-HLA interactions was related to shorter overall survival, whereas KIR2DS1/C2 interaction, in the absence of other aKIR interactions, was associated with longer survival. Three major NK-cell transcriptional profiles were identified: mature cytotoxic, immature/regulatory, and adaptive cytotoxic. The adaptive-like transcriptional profile was associated with longer survival.</p><p><strong>Conclusions: </strong>In conclusion, aKIR/HLA-I interactions were associated with cancer patient outcomes. In particular, KIR2DS1/C2 interaction in the absence of other activating signals was associated with adaptive NK-cell transcriptomic profiles and improved survival. Understanding the mechanisms underlying effective NK-cell-mediated tumor immunity may provide new opportunities for patients with refractory tumors.</p>","PeriodicalId":48714,"journal":{"name":"Oncoimmunology","volume":"15 1","pages":"2756722"},"PeriodicalIF":6.2,"publicationDate":"2026-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149326293","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Unlocking the therapeutic potential of immuno-radiotherapy: insights from preclinical and clinical research. 释放免疫放疗的治疗潜力:来自临床前和临床研究的见解。
IF 6.5 2区 医学 Q1 IMMUNOLOGY Pub Date : 2026-12-31 Epub Date: 2026-01-05 DOI: 10.1080/2162402X.2025.2608436
M M Cogels, A de Caluwé, L Buisseret, S Penninckx

The immunomodulatory potential of radiotherapy provides a strong rationale for its combination with immunotherapies and other immunostimulatory agents. However, current combinations yield suboptimal clinical benefits. As the mechanisms behind radiotherapy-induced immunomodulation are gradually unraveled, various key factors have been identified as critical modulators of this process, opening new possibilities for adapting radiotherapy to immunotherapy. Here, we discuss seven factors: dose‒fractionation regimens of radiotherapy (RT), sequence and timing of RT and immunotherapy, radiation field, type of ionizing radiation, normal tissue effects, choice of the lesion to irradiate and identification of biomarkers. Preclinical and clinical studies on the combination of immunotherapy and radiotherapy are discussed, novel immunotherapeutic approaches are highlighted and improvements in study design are suggested.

放射治疗的免疫调节潜能为其与免疫疗法和其他免疫刺激剂的联合治疗提供了强有力的理论依据。然而,目前的联合用药不能产生最佳的临床疗效。随着放疗诱导的免疫调节机制逐渐被揭示,各种关键因素已被确定为这一过程的关键调节剂,为使放疗适应免疫治疗开辟了新的可能性。在这里,我们讨论了七个因素:放射治疗的剂量分割方案,放射治疗和免疫治疗的顺序和时间,放射场,电离辐射类型,正常组织效应,照射病灶的选择和生物标志物的鉴定。本文讨论了免疫治疗与放疗结合的临床前和临床研究,重点介绍了新的免疫治疗方法,并提出了研究设计的改进建议。
{"title":"Unlocking the therapeutic potential of immuno-radiotherapy: insights from preclinical and clinical research.","authors":"M M Cogels, A de Caluwé, L Buisseret, S Penninckx","doi":"10.1080/2162402X.2025.2608436","DOIUrl":"10.1080/2162402X.2025.2608436","url":null,"abstract":"<p><p>The immunomodulatory potential of radiotherapy provides a strong rationale for its combination with immunotherapies and other immunostimulatory agents. However, current combinations yield suboptimal clinical benefits. As the mechanisms behind radiotherapy-induced immunomodulation are gradually unraveled, various key factors have been identified as critical modulators of this process, opening new possibilities for adapting radiotherapy to immunotherapy. Here, we discuss seven factors: dose‒fractionation regimens of radiotherapy (RT), sequence and timing of RT and immunotherapy, radiation field, type of ionizing radiation, normal tissue effects, choice of the lesion to irradiate and identification of biomarkers. Preclinical and clinical studies on the combination of immunotherapy and radiotherapy are discussed, novel immunotherapeutic approaches are highlighted and improvements in study design are suggested.</p>","PeriodicalId":48714,"journal":{"name":"Oncoimmunology","volume":"15 1","pages":"2608436"},"PeriodicalIF":6.5,"publicationDate":"2026-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12778880/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145906970","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The double face of IL-1β in lung cancer. IL-1β在肺癌中的双重面目。
IF 6.2 2区 医学 Q1 IMMUNOLOGY Pub Date : 2026-12-31 Epub Date: 2026-02-03 DOI: 10.1080/2162402X.2026.2622661
Cédric Rébé, Anaïs Perrichet, François Ghiringhelli

Interleukin (IL)-1β is known to promote lung cancer growth in both humans and mice. However, in the context of the current standard of care, which includes chemotherapy and immune checkpoint inhibitors, IL-1β can overcome resistance.

已知白细胞介素(IL)-1β可促进人类和小鼠肺癌的生长。然而,在目前的治疗标准下,包括化疗和免疫检查点抑制剂,IL-1β可以克服耐药性。
{"title":"The double face of IL-1β in lung cancer.","authors":"Cédric Rébé, Anaïs Perrichet, François Ghiringhelli","doi":"10.1080/2162402X.2026.2622661","DOIUrl":"10.1080/2162402X.2026.2622661","url":null,"abstract":"<p><p>Interleukin (IL)-1β is known to promote lung cancer growth in both humans and mice. However, in the context of the current standard of care, which includes chemotherapy and immune checkpoint inhibitors, IL-1β can overcome resistance.</p>","PeriodicalId":48714,"journal":{"name":"Oncoimmunology","volume":"15 1","pages":"2622661"},"PeriodicalIF":6.2,"publicationDate":"2026-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12885432/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146114685","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
In vitro generated macrophages reflect the immunosuppressive phenotype of in vivo glioblastoma-associated macrophages. 体外生成的巨噬细胞反映了体内胶质母细胞瘤相关巨噬细胞的免疫抑制表型。
IF 6.2 2区 医学 Q1 IMMUNOLOGY Pub Date : 2026-12-31 Epub Date: 2026-01-25 DOI: 10.1080/2162402X.2025.2610562
Matthew Nazzaro, Elaine R Mardis, Mykyta Artomov, Ella Juenger, Justin Lyberger, Mark Damante, Gregory Behbehani, Susobhan Sarkar, Prajwal Rajappa

Glioblastoma (GBM) is the most common primary central nervous system tumor with a dismal prognosis and limited treatment options. Recent success utilizing immunotherapies for treating other solid tumors have been largely unsuccessful in GBM. One of the primary mechanisms of GBM immunotherapeutic resistance is because of excessive infiltration of myeloid cells that create an immunosuppressive tumor microenvironment (TME). Among these infiltrating myeloid cells, tumor-associated macrophages (TAMs), comprise a substantial portion of the TME and are associated with poor prognosis in GBM patients. Researchers have only recently begun to dissect the dynamics and complexity of TAMs. However, reliable and reproducible translational methods for generating GBM TAMs in vitro are lacking. Here, we have investigated an in vitro, reproducible murine-based model for bone marrow-derived, glioma-educated macrophages (gTAMs) and performed rigorous analysis to expand our understanding of gTAMs to provide a validated tool for investigating therapeutic response.

胶质母细胞瘤(GBM)是最常见的原发性中枢神经系统肿瘤,预后差,治疗方案有限。最近利用免疫疗法治疗其他实体瘤的成功在GBM中基本上是不成功的。GBM免疫治疗耐药的主要机制之一是骨髓细胞过度浸润,产生免疫抑制肿瘤微环境(TME)。在这些浸润性骨髓细胞中,肿瘤相关巨噬细胞(tam)占TME的很大一部分,并与GBM患者的不良预后相关。研究人员直到最近才开始剖析tam的动力学和复杂性。然而,缺乏可靠和可重复的体外生成GBM tam的翻译方法。在这里,我们研究了一种体外可重复的小鼠骨髓来源的胶质瘤巨噬细胞(gtam)模型,并进行了严格的分析,以扩大我们对gtam的理解,为研究治疗反应提供一种有效的工具。
{"title":"<i>In vitro</i> generated macrophages reflect the immunosuppressive phenotype of <i>in vivo</i> glioblastoma-associated macrophages.","authors":"Matthew Nazzaro, Elaine R Mardis, Mykyta Artomov, Ella Juenger, Justin Lyberger, Mark Damante, Gregory Behbehani, Susobhan Sarkar, Prajwal Rajappa","doi":"10.1080/2162402X.2025.2610562","DOIUrl":"10.1080/2162402X.2025.2610562","url":null,"abstract":"<p><p>Glioblastoma (GBM) is the most common primary central nervous system tumor with a dismal prognosis and limited treatment options. Recent success utilizing immunotherapies for treating other solid tumors have been largely unsuccessful in GBM. One of the primary mechanisms of GBM immunotherapeutic resistance is because of excessive infiltration of myeloid cells that create an immunosuppressive tumor microenvironment (TME). Among these infiltrating myeloid cells, tumor-associated macrophages (TAMs), comprise a substantial portion of the TME and are associated with poor prognosis in GBM patients. Researchers have only recently begun to dissect the dynamics and complexity of TAMs. However, reliable and reproducible translational methods for generating GBM TAMs <i>in vitro</i> are lacking. Here, we have investigated an <i>in vitro,</i> reproducible murine-based model for bone marrow-derived, glioma-educated macrophages (gTAMs) and performed rigorous analysis to expand our understanding of gTAMs to provide a validated tool for investigating therapeutic response.</p>","PeriodicalId":48714,"journal":{"name":"Oncoimmunology","volume":"15 1","pages":"2610562"},"PeriodicalIF":6.2,"publicationDate":"2026-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12851398/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146047314","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Contrasting functions of CD73 and adenosine in CD8+ T-cell exhaustion during antitumor immunity. CD73和腺苷在抗肿瘤免疫过程中CD8+ t细胞衰竭中的作用对比
IF 6.2 2区 医学 Q1 IMMUNOLOGY Pub Date : 2026-12-31 Epub Date: 2026-03-13 DOI: 10.1080/2162402X.2026.2642458
Juan Saavedra-Almarza, Solange Gouët, Felipe Malgue, Catalina Bascuñan, Andrés Hernández-Oliveras, Joaquín De la Rosa, Javiera Reyes-Alvarez, Camilo Villaman, José Corrales-Bermúdez, Justine Castañeda, Moira García-Gómez, Alberto J M Martin, Álvaro Lladser, Mario Rosemblatt, María Rosa Bono, Daniela Sauma

T-cell exhaustion is a state of functional decline in T cells, driven by chronic antigen exposure and inhibitory signals within the tumor microenvironment. Exhausted CD8+ T cells (Tex) derive from precursor exhausted T cells (Tpex), a self-renewing population responsible for the proliferative burst in anti-PD-1 therapies. Exhausted T cells are exposed to adenosine in the tumor, yet the role of the CD73/adenosine axis and Tpex/Tex differentiation remains unclear. Using an in vitro model for CD8+ T-cell exhaustion, we found that CD73 expression increased during Tpex formation and that its expression was negatively correlated with Tex generation. CD73-deficient OT-I cells (OT-I/CD73KO) showed impaired activation and reduced progression to Tex. Moreover, we demonstrated that CD73 promotes transcriptional expression of the adenosine receptor A2A (A2AR). RNA-seq analysis of exhausted OT-I/CD73KO cells revealed a more stem-like transcriptomic profile and enrichment in genes associated with the immune response compared to their OT-I counterparts. In vivo, the cotransfer of naïve OT-I/CD73KO and OT-I antigen-specific CD8⁺ T cells into tumor-bearing mice resulted in increased Tpex frequency and numbers among OT-I/CD73KO cells in tumors. Conversely, in vitro exhaustion in the presence of A2AR agonists decreased Tex frequency and activation/exhaustion markers, while increasing CD73 and CD62L, which are markers associated with stemness. Supporting this, A2AR blockade with SYN115 in tumor-bearing mice reduced Tpex markers and increased Tex differentiation. Altogether, our data suggest that CD73 promotes Tpex-to-Tex differentiation, whereas adenosine A2AR signaling supports Tpex maintenance in the tumor microenvironment.

T细胞衰竭是T细胞功能下降的一种状态,由肿瘤微环境中的慢性抗原暴露和抑制信号驱动。耗竭的CD8+ T细胞(Tex)来源于前体耗竭T细胞(Tpex),这是一种自我更新的细胞群,在抗pd -1治疗中负责增殖性爆发。耗尽的T细胞在肿瘤中暴露于腺苷,但CD73/腺苷轴和Tpex/Tex分化的作用尚不清楚。通过体外CD8+ t细胞衰竭模型,我们发现CD73的表达在Tpex形成过程中增加,并且其表达与Tex的产生呈负相关。cd73缺陷的OT-I细胞(OT-I/CD73KO)表现出激活受损和向Tex的进展减少。此外,我们证明CD73促进腺苷受体A2A (A2AR)的转录表达。耗尽的OT-I/CD73KO细胞的RNA-seq分析显示,与OT-I细胞相比,它们的转录组谱更像干细胞,与免疫应答相关的基因也更丰富。在体内,naïve OT-I/CD73KO和OT-I抗原特异性CD8 + T细胞共转移到肿瘤小鼠体内,导致肿瘤中OT-I/CD73KO细胞中Tpex频率和数量增加。相反,在A2AR激动剂存在下的体外衰竭降低了Tex频率和激活/衰竭标记,同时增加了CD73和CD62L,这是与干性相关的标记。支持这一点的是,在肿瘤小鼠中,用SYN115阻断A2AR可减少Tpex标记物并增加Tex分化。总之,我们的数据表明CD73促进Tpex到tex的分化,而腺苷A2AR信号支持肿瘤微环境中Tpex的维持。
{"title":"Contrasting functions of CD73 and adenosine in CD8+ T-cell exhaustion during antitumor immunity.","authors":"Juan Saavedra-Almarza, Solange Gouët, Felipe Malgue, Catalina Bascuñan, Andrés Hernández-Oliveras, Joaquín De la Rosa, Javiera Reyes-Alvarez, Camilo Villaman, José Corrales-Bermúdez, Justine Castañeda, Moira García-Gómez, Alberto J M Martin, Álvaro Lladser, Mario Rosemblatt, María Rosa Bono, Daniela Sauma","doi":"10.1080/2162402X.2026.2642458","DOIUrl":"10.1080/2162402X.2026.2642458","url":null,"abstract":"<p><p>T-cell exhaustion is a state of functional decline in T cells, driven by chronic antigen exposure and inhibitory signals within the tumor microenvironment. Exhausted CD8+ T cells (Tex) derive from precursor exhausted T cells (Tpex), a self-renewing population responsible for the proliferative burst in anti-PD-1 therapies. Exhausted T cells are exposed to adenosine in the tumor, yet the role of the CD73/adenosine axis and Tpex/Tex differentiation remains unclear. Using an <i>in vitro</i> model for CD8+ T-cell exhaustion, we found that CD73 expression increased during Tpex formation and that its expression was negatively correlated with Tex generation. CD73-deficient OT-I cells (OT-I/CD73KO) showed impaired activation and reduced progression to Tex. Moreover, we demonstrated that CD73 promotes transcriptional expression of the adenosine receptor A2A (A2AR). RNA-seq analysis of exhausted OT-I/CD73KO cells revealed a more stem-like transcriptomic profile and enrichment in genes associated with the immune response compared to their OT-I counterparts. <i>In vivo</i>, the cotransfer of naïve OT-I/CD73KO and OT-I antigen-specific CD8⁺ T cells into tumor-bearing mice resulted in increased Tpex frequency and numbers among OT-I/CD73KO cells in tumors. Conversely, <i>in vitro</i> exhaustion in the presence of A2AR agonists decreased Tex frequency and activation/exhaustion markers, while increasing CD73 and CD62L, which are markers associated with stemness. Supporting this, A2AR blockade with SYN115 in tumor-bearing mice reduced Tpex markers and increased Tex differentiation. Altogether, our data suggest that CD73 promotes Tpex-to-Tex differentiation, whereas adenosine A2AR signaling supports Tpex maintenance in the tumor microenvironment.</p>","PeriodicalId":48714,"journal":{"name":"Oncoimmunology","volume":"15 1","pages":"2642458"},"PeriodicalIF":6.2,"publicationDate":"2026-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12990944/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147445645","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Characterization of persistent HPV-specific activated T cells in head and neck squamous cell carcinoma. 头颈部鳞状细胞癌中持续hpv特异性活化T细胞的特征。
IF 6.2 2区 医学 Q1 IMMUNOLOGY Pub Date : 2026-12-31 Epub Date: 2026-07-26 DOI: 10.1080/2162402X.2026.2707808
Hiromasa Ishihara, Hirofumi Shibata, Daisuke Muraoka, Ayako Demachi-Okamura, Takanari Okamoto, Ryo Mizuta, Yasunori Fukushima, Yusuke Sugita, Aiko Ogasawara, Reina Nishida, Shintaro Beppu, Hoshino Terada, Daisuke Nishikawa, Hidenori Suzuki, Katsuhiro Masago, Eiichi Sasaki, Noriaki Sakakura, Rui Yamaguchi, Nobuhiro Hanai, Takenori Ogawa, Hirokazu Matsushita

Background: Human papillomavirus-positive oropharyngeal squamous cell carcinoma (HPV + OPSCC) generally has favorable outcomes yet remains prone to late recurrence. Durable control likely depends on persistent tumor-specific CD8+ T cells, but their persistence and function in metastasis are poorly understood.

Methods: We integrated bulk RNA sequencing (n = 56) with single-cell RNA and paired T-cell receptor (TCR) sequencing of tumor-infiltrating CD8+ T cells (n = 4), including a longitudinal primary-lung metastasis pair obtained three years after curative therapy. HPV genotyping, HLA typing, epitope prediction, and NFAT-reporter Jurkat-luciferase assays were used to identify and functionally validate HPV16 E6/E7-specific TCRs. Repertoire tracking and single-cell/bulk transcriptomics were evaluated.

Results: HPV + tumors showed higher inferred CD8+ T cell infiltration and more favorable prognosis than HPV- tumors. Single-cell analysis revealed oligoclonally expanded exhausted clusters enriched in HPV tumor-specific CD8+ T cells. We isolated and functionally validated nine patient-derived HPV16 E6/E7-specific TCRs. High-avidity receptors recognizing an alternatively spliced region in E6 (aa 49-110; E6*) persisted in metastatic lesions, whereas lower-avidity clones, including an E7_11-19-specific TCR currently under clinical investigation, were lost. Compared with the primary tumor, metastatic lesions showed reduced stem-like/TCF7-associated CD8+ T-cell populations and enrichment of HPV-specific CD8+ T cells expressing KLRB1 and ZNF683, consistent with a tissue-adapted TRM-like transcriptional state with inhibitory signaling features.

Conclusions: High-avidity, KLRB1 + HPV-specific CD8+ T cells represent a persistent effector subset with prognostic and therapeutic relevance to HPV + OPSCC. Their persistence in metastatic lesions and association with reduced recurrence risk support further investigation of KLRB1-associated HPV-reactive T-cell states as biomarkers and immunotherapeutic targets.

背景:人乳头瘤病毒阳性的口咽鳞状细胞癌(HPV + OPSCC)通常具有良好的预后,但仍然容易晚期复发。持久的控制可能取决于持续的肿瘤特异性CD8+ T细胞,但它们在转移中的持久性和功能尚不清楚。方法:我们将大量RNA测序(n = 56)与肿瘤浸润性CD8+ T细胞(n = 4)的单细胞RNA和配对T细胞受体(TCR)测序(n = 4)结合起来,包括治疗后3年获得的纵向原发性肺转移对。使用HPV基因分型、HLA分型、表位预测和nfat报告基因Jurkat-luciferase检测来鉴定和功能验证HPV16 E6/ e7特异性tcr。曲目跟踪和单细胞/批量转录组学进行评估。结果:HPV +肿瘤提示CD8+ T细胞浸润率高于HPV-肿瘤,预后良好。单细胞分析显示,在HPV肿瘤特异性CD8+ T细胞中富集了寡克隆扩增的耗尽簇。我们分离并功能验证了9个患者来源的HPV16 E6/ e7特异性tcr。识别E6中选择性剪接区域的高亲和性受体(aa 49-110; E6*)在转移灶中持续存在,而低亲和性克隆(包括目前正在临床研究的e7_11 -19特异性TCR)丢失。与原发肿瘤相比,转移灶显示干细胞样/ tcf7相关CD8+ T细胞群减少,表达KLRB1和ZNF683的hpv特异性CD8+ T细胞富集,与具有抑制信号特征的组织适应性trm样转录状态一致。结论:高频率,KLRB1 + HPV特异性CD8+ T细胞代表一个持久的效应亚群,与HPV + OPSCC的预后和治疗相关。它们在转移性病变中的持久性和与降低复发风险的相关性支持进一步研究klrb1相关的hpv反应性t细胞状态作为生物标志物和免疫治疗靶点。
{"title":"Characterization of persistent HPV-specific activated T cells in head and neck squamous cell carcinoma.","authors":"Hiromasa Ishihara, Hirofumi Shibata, Daisuke Muraoka, Ayako Demachi-Okamura, Takanari Okamoto, Ryo Mizuta, Yasunori Fukushima, Yusuke Sugita, Aiko Ogasawara, Reina Nishida, Shintaro Beppu, Hoshino Terada, Daisuke Nishikawa, Hidenori Suzuki, Katsuhiro Masago, Eiichi Sasaki, Noriaki Sakakura, Rui Yamaguchi, Nobuhiro Hanai, Takenori Ogawa, Hirokazu Matsushita","doi":"10.1080/2162402X.2026.2707808","DOIUrl":"10.1080/2162402X.2026.2707808","url":null,"abstract":"<p><strong>Background: </strong>Human papillomavirus-positive oropharyngeal squamous cell carcinoma (HPV + OPSCC) generally has favorable outcomes yet remains prone to late recurrence. Durable control likely depends on persistent tumor-specific CD8+ T cells, but their persistence and function in metastasis are poorly understood.</p><p><strong>Methods: </strong>We integrated bulk RNA sequencing (<i>n</i> = 56) with single-cell RNA and paired T-cell receptor (TCR) sequencing of tumor-infiltrating CD8+ T cells (<i>n</i> = 4), including a longitudinal primary-lung metastasis pair obtained three years after curative therapy. HPV genotyping, HLA typing, epitope prediction, and NFAT-reporter Jurkat-luciferase assays were used to identify and functionally validate HPV16 E6/E7-specific TCRs. Repertoire tracking and single-cell/bulk transcriptomics were evaluated.</p><p><strong>Results: </strong>HPV + tumors showed higher inferred CD8+ T cell infiltration and more favorable prognosis than HPV- tumors. Single-cell analysis revealed oligoclonally expanded exhausted clusters enriched in HPV tumor-specific CD8+ T cells. We isolated and functionally validated nine patient-derived HPV16 E6/E7-specific TCRs. High-avidity receptors recognizing an alternatively spliced region in E6 (aa 49-110; E6*) persisted in metastatic lesions, whereas lower-avidity clones, including an E7_11-19-specific TCR currently under clinical investigation, were lost. Compared with the primary tumor, metastatic lesions showed reduced stem-like/TCF7-associated CD8+ T-cell populations and enrichment of HPV-specific CD8+ T cells expressing <i>KLRB1</i> and <i>ZNF683</i>, consistent with a tissue-adapted TRM-like transcriptional state with inhibitory signaling features.</p><p><strong>Conclusions: </strong>High-avidity, <i>KLRB1</i> + HPV-specific CD8+ T cells represent a persistent effector subset with prognostic and therapeutic relevance to HPV + OPSCC. Their persistence in metastatic lesions and association with reduced recurrence risk support further investigation of <i>KLRB1</i>-associated HPV-reactive T-cell states as biomarkers and immunotherapeutic targets.</p>","PeriodicalId":48714,"journal":{"name":"Oncoimmunology","volume":"15 1","pages":"2707808"},"PeriodicalIF":6.2,"publicationDate":"2026-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13418702/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148594270","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Integrating tumor and immune cell transcriptomics to predict immune checkpoint inhibitor primary resistance in metastatic melanoma. 整合肿瘤和免疫细胞转录组学预测转移性黑色素瘤中免疫检查点抑制剂的原发性耐药性。
IF 6.2 2区 医学 Q1 IMMUNOLOGY Pub Date : 2026-12-31 Epub Date: 2026-03-30 DOI: 10.1080/2162402X.2026.2650234
Juan Luis Onieva, Elisabeth Pérez-Ruiz, Ville Vilkki, Miguel Berciano-Guerrero, Laura Figueroa-Ortiz, Manuel Zalabardo, Beatriz Martínez-Gálvez, Isabel Barragán, Antonio Rueda-Domínguez

The emergence of immune checkpoint inhibitors (ICIs) has transformed the treatment landscape of metastatic melanoma. However, despite its success, reliable biomarkers for predicting primary resistance are not available in clinical practice. This study seeks to identify predictors of primary resistance based on novel gene expression signatures. The transcriptomic profile of the tumor microenvironment was analyzed using tissue samples from 46 metastatic cutaneous melanoma patients collected prior to the initiation of ICIs therapy. A primary resistance predictive model was trained with the Discovery FFPE RNA-seq subcohort and validated using an independent external cohort of 54 samples. Additionally, liquid biopsy samples from peripheral blood mononuclear cells were analyzed in 8 patients using single-cell RNA sequencing (scRNA-seq) and in 46 patients using flow cytometry. We identified an 82-gene transcriptomic signature composed of tumor- and immune-related genes that stratifies metastatic cutaneous melanoma patients based on primary resistance to ICIs, with key markers including CXCL13, WDR63, MZB1, FDCSP, IGKC and GRIK3. This signature achieved an AUC of 0.814. Immune deconvolution guided by scRNA-seq revealed four immune cell subsets (Plasma cells, Pre-B cells, memory CD4⁺ T cells, and naive CD4⁺ T cells) as prognostic indicators of resistance. We propose a transcriptomic biomarker signature that accurately predicts primary resistance to ICIs in metastatic cutaneous melanoma. Through the integration of immune deconvolution with circulating immune cell profiles, we derived an ImmuneSignature linked to patient survival. By combining these approaches, we provide a framework for enhancing the prediction of immunotherapy outcomes and offer a novel strategy for identifying therapeutic targets to overcome resistance.

免疫检查点抑制剂(ICIs)的出现改变了转移性黑色素瘤的治疗前景。然而,尽管它取得了成功,但在临床实践中还没有可靠的生物标志物来预测原发性耐药性。本研究旨在根据新的基因表达特征确定原发性耐药的预测因子。肿瘤微环境的转录组谱分析使用的是在ICIs治疗开始前收集的46例转移性皮肤黑色素瘤患者的组织样本。使用Discovery FFPE RNA-seq亚队列训练初级耐药预测模型,并使用54个样本的独立外部队列进行验证。此外,使用单细胞RNA测序(scRNA-seq)分析8例患者外周血单个核细胞的液体活检样本,使用流式细胞术分析46例患者。我们确定了一个由肿瘤和免疫相关基因组成的82个基因转录组特征,该特征基于对ICIs的原发性耐药性对转移性皮肤黑色素瘤患者进行分层,关键标志物包括CXCL13、WDR63、MZB1、FDCSP、IGKC和GRIK3。该特征的AUC为0.814。scRNA-seq引导下的免疫反褶积揭示了四种免疫细胞亚群(浆细胞、前b细胞、记忆CD4 + T细胞和幼稚CD4 + T细胞)是耐药的预后指标。我们提出了一种转录组生物学标记,可以准确预测转移性皮肤黑色素瘤对ICIs的原发性耐药性。通过将免疫反褶积与循环免疫细胞谱相结合,我们获得了与患者生存相关的免疫特征。通过结合这些方法,我们为增强免疫治疗结果的预测提供了一个框架,并为确定治疗靶点以克服耐药性提供了一种新的策略。
{"title":"Integrating tumor and immune cell transcriptomics to predict immune checkpoint inhibitor primary resistance in metastatic melanoma.","authors":"Juan Luis Onieva, Elisabeth Pérez-Ruiz, Ville Vilkki, Miguel Berciano-Guerrero, Laura Figueroa-Ortiz, Manuel Zalabardo, Beatriz Martínez-Gálvez, Isabel Barragán, Antonio Rueda-Domínguez","doi":"10.1080/2162402X.2026.2650234","DOIUrl":"10.1080/2162402X.2026.2650234","url":null,"abstract":"<p><p>The emergence of immune checkpoint inhibitors (ICIs) has transformed the treatment landscape of metastatic melanoma. However, despite its success, reliable biomarkers for predicting primary resistance are not available in clinical practice. This study seeks to identify predictors of primary resistance based on novel gene expression signatures. The transcriptomic profile of the tumor microenvironment was analyzed using tissue samples from 46 metastatic cutaneous melanoma patients collected prior to the initiation of ICIs therapy. A primary resistance predictive model was trained with the Discovery FFPE RNA-seq subcohort and validated using an independent external cohort of 54 samples. Additionally, liquid biopsy samples from peripheral blood mononuclear cells were analyzed in 8 patients using single-cell RNA sequencing (scRNA-seq) and in 46 patients using flow cytometry. We identified an 82-gene transcriptomic signature composed of tumor- and immune-related genes that stratifies metastatic cutaneous melanoma patients based on primary resistance to ICIs, with key markers including <i>CXCL13, WDR63, MZB1, FDCSP, IGKC</i> and <i>GRIK3</i>. This signature achieved an AUC of 0.814. Immune deconvolution guided by scRNA-seq revealed four immune cell subsets (Plasma cells, Pre-B cells, memory CD4⁺ T cells, and naive CD4⁺ T cells) as prognostic indicators of resistance. We propose a transcriptomic biomarker signature that accurately predicts primary resistance to ICIs in metastatic cutaneous melanoma. Through the integration of immune deconvolution with circulating immune cell profiles, we derived an ImmuneSignature linked to patient survival. By combining these approaches, we provide a framework for enhancing the prediction of immunotherapy outcomes and offer a novel strategy for identifying therapeutic targets to overcome resistance.</p>","PeriodicalId":48714,"journal":{"name":"Oncoimmunology","volume":"15 1","pages":"2650234"},"PeriodicalIF":6.2,"publicationDate":"2026-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13048569/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147582049","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Oncoimmunology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
﹀
mjeditor
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1